117 related articles for article (PubMed ID: 31407032)
81. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
82. Is the Ki-67 labelling index ready for clinical use?
Jonat W; Arnold N
Ann Oncol; 2011 Mar; 22(3):500-502. PubMed ID: 21343384
[No Abstract] [Full Text] [Related]
83. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.
Miyashita M; Ishida T; Ishida K; Tamaki K; Amari M; Watanabe M; Ohuchi N; Sasano H
Virchows Arch; 2011 Jan; 458(1):65-72. PubMed ID: 21104095
[TBL] [Abstract][Full Text] [Related]
84. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory.
Thomson TA; Zhou C; Chu C; Knight B
Am J Clin Pathol; 2009 Dec; 132(6):899-905. PubMed ID: 19926582
[TBL] [Abstract][Full Text] [Related]
85. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.
Thike AA; Cheok PY; Jara-Lazaro AR; Tan B; Tan P; Tan PH
Mod Pathol; 2010 Jan; 23(1):123-33. PubMed ID: 19855377
[TBL] [Abstract][Full Text] [Related]
86. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.
Fluge Ø; Gravdal K; Carlsen E; Vonen B; Kjellevold K; Refsum S; Lilleng R; Eide TJ; Halvorsen TB; Tveit KM; Otte AP; Akslen LA; Dahl O;
Br J Cancer; 2009 Oct; 101(8):1282-9. PubMed ID: 19773751
[TBL] [Abstract][Full Text] [Related]
87. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
88. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
[TBL] [Abstract][Full Text] [Related]
89. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
[TBL] [Abstract][Full Text] [Related]
90. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
91. Platinum-based chemotherapy in triple-negative breast cancer.
Sirohi B; Arnedos M; Popat S; Ashley S; Nerurkar A; Walsh G; Johnston S; Smith IE
Ann Oncol; 2008 Nov; 19(11):1847-52. PubMed ID: 18567607
[TBL] [Abstract][Full Text] [Related]
92. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
[TBL] [Abstract][Full Text] [Related]
93. Triple-negative breast cancer: clinical features and patterns of recurrence.
Dent R; Trudeau M; Pritchard KI; Hanna WM; Kahn HK; Sawka CA; Lickley LA; Rawlinson E; Sun P; Narod SA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4429-34. PubMed ID: 17671126
[TBL] [Abstract][Full Text] [Related]
94. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
de Azambuja E; Cardoso F; de Castro G; Colozza M; Mano MS; Durbecq V; Sotiriou C; Larsimont D; Piccart-Gebhart MJ; Paesmans M
Br J Cancer; 2007 May; 96(10):1504-13. PubMed ID: 17453008
[TBL] [Abstract][Full Text] [Related]
95. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
96. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
Vincent-Salomon A; Gruel N; Lucchesi C; MacGrogan G; Dendale R; Sigal-Zafrani B; Longy M; Raynal V; Pierron G; de Mascarel I; Taris C; Stoppa-Lyonnet D; Pierga JY; Salmon R; Sastre-Garau X; Fourquet A; Delattre O; de Cremoux P; Aurias A
Breast Cancer Res; 2007; 9(2):R24. PubMed ID: 17417968
[TBL] [Abstract][Full Text] [Related]
97. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
98. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
[TBL] [Abstract][Full Text] [Related]
99. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
100. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
Ruiz C; Seibt S; Al Kuraya K; Siraj AK; Mirlacher M; Schraml P; Maurer R; Spichtin H; Torhorst J; Popovska S; Simon R; Sauter G
Int J Cancer; 2006 May; 118(9):2190-4. PubMed ID: 16331604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
